VanEck Junior Gold Miners vs Novavax Inc — how do they compare? VanEck Junior Gold Miners trades at $119.25, while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: VanEck Junior Gold Miners is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| GDXJ | NVAX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $11.19 |
52-Week Low | $71.22 | $6.22 |
Market Cap | — | $1.31B |
Enterprise Value | — | $889.30M |
Signals from Pluang's Aura AI — not financial advice
GDXJ (VanEck Junior Gold Miners ETF) trades at $119.44, up 0.56% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows mixed sentiment with institutional selling by Amundi reducing its stake by 50.5% in the latest quarter (Defense World, August 6, 2026). Recent underperformance versus peers and gold ETFs highlights challenges in the junior gold mining sector.
Outlook remains cautious due to high RSI levels suggesting overbought conditions and sector-specific headwinds. Investment opportunity hinges on gold price momentum, but risks include Federal Reserve policy uncertainty and competitive pressure from senior miners. Analyst sentiment is neutral with concerns about portfolio composition and small-cap exposure.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Trailing returns across standard periods
Latest headlines on both assets
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →